Anocca ansöker om klinisk prövning för VIDAR-1 vid bukspottkörtelcancer
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer.
Application to the European Medicines Agency (EMA) covers ANOC-001 as the initial product in the company’s VIDAR-1 Phase I/II multi-asset programme targeting mutated KRAS in advanced pancreatic cancer. ANOC-001 is the first product to enter human trials from Anocca’s robust T-cell receptor T-cell therapy (TCR-T) pipeline and, subject to approval, the trial will start during Q2, 2025. Anocca is focused on developing innovative precision TCR-T cell therapies as potential new solutions in cancers with high unmet medical need.
